Y-mabs files for EU approval for pediatric cancer drug

On Tuesday, Danish biotech firm Y-mabs submitted an application to get approval for the cancer drug omburtamab, according to the firm.
Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750
Photo: PIROSCHKA VAN DE WOUW/REUTERS / X06750
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN

US-Danish Biotech firm Y-mabs, which is listed on US Stock Exchange Nasdaq, has submitted a new application for marketing authorization for a cancer treatment. This was revealed after the close of trading on Tuesday.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading